CRL Charles River Laboratories International Inc.

Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville

Charles River Laboratories International, Inc. (NYSE: CRL) has announced the opening of a new Charles River Accelerator and Development Lab (CRADL®) facility on Chestnut Street in Somerville, Massachusetts, an emerging life sciences hub. The facility is strategically co-located with Nest.Bio, a provider of rentable BSL-2 laboratory and office space. The Chestnut Street location will address an increased demand for more flexible vivarium and bench space, as well as on-demand in vivo study support services within the heart of Massachusetts’ industry-leading biopharmaceutical sector.

“We are excited to bring CRADL to Somerville’s Brickbottom District, an emerging life science hub for biotech development in which startups unable to find lab space in the increasingly crowded Cambridge environment can thrive,” said Colin Dunn, Ph.D., Corporate Senior Vice President, Global Research Models & Services, Charles River. “CRADL’s scalable contract vivarium space, combined with Charles River’s extensive preclinical network, supports clients in starting projects quickly, without the costly burden of building infrastructure.”

CRADL® is the leading space for clients to launch or expand their drug research programs, with the added benefit of access to Charles River’s complete portfolio of integrated drug discovery and non-clinical development resources.

The new Somerville facility is strategically situated less than a mile from the established industry presence in Kendall Square. The building offers a unique coexistence of private lab suites, rentable lab benches, and office space on the same floor to enable seamless communication, collaboration, and productivity. This distinctive setup can be particularly advantageous for startup organizations, providing an efficient and streamlined environment for both research and administrative functions.

Expanding Access and Expertise to Global Ecosystems through CRADL

With the addition of a fourth Massachusetts site, the CRADL Vivarium Network operates nearly 30 facilities in key biohubs, including: San Francisco, San Diego, Seattle, Philadelphia, Chicago, Thousand Oaks, Shanghai, Chengdu and London. This network supports the growth of the entire biotech ecosystem in each city, allowing researchers to rapidly engage in their research while maintaining the flexibility to relocate or co-locate, knowing they will have reliable, high-quality facilities nearby.

Charles River is hosting a grand opening for CRADL Somerville on July 31, 2024, including guided tours and equipment demonstrations with expert staff. To learn more and register, visit: .

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit .

EN
06/06/2024

Underlying

Reports on Charles River Laboratories International Inc.

Charles River Laboratories Int'l, Inc.: Update to credit analysis

Charles River's credit profile reflects its strong and consistent free cash flow, offset by its sensitivity to R&D budgets of clients and research funding availability.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Charles River Laboratories Int'l, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 23 December 2025 in which we reassessed the appropriateness of the r...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch